Narrow your search
Listing 1 - 10 of 26 << page
of 3
>>
Sort by

Book
Immunoglobulin therapy in the 21st century: the dark side of the moon
Authors: --- ---
Year: 2015 Publisher: Frontiers Media SA

Loading...
Export citation

Choose an application

Bookmark

Abstract

In the early decades since the introduction in the early '80s of immunoglobulin therapy many studies tried to identify which clinical indications might benefit from the therapy, which treatment’s schedules are effective and safe. It is universally accepted that immunoglobulin therapy is a life-saving treatment in patients with PID. The rise of new indications for further different clinical conditions resulted in a steady increase in demand for immunoglobulins. Currently the consumption of immunoglobulin for PID represents a small fraction of the market. In the recent past we have been observing: 1) An increase in the demand for plasma and in the consequent need to increase the number of donors; 2) Changes in methods to improve IgG recovery and to increase productivity as a response to growing clinical demand; 3) Introduction of immunoglobulin treatments with higher concentration; 4) Changes in the timing of administration with an increase in the rate of infusion; 5) Introduction of immunoglobulin treatment administered subcutaneously mainly confined initially to patients with PID and later extended to other clinical indications which often require higher volumes of infusion. Doctors following patients with PID were initially alarmed only to a possible risk of shortage. More relevant and less discussed appear the possible consequences of: 1) the risk of an improper transfer of information on treatments from a clinical indication to another. In particular, the idea of a mere replacement function in patients with PID might possibly be borrowed from the model of other clinical conditions requiring a replacement such as haemophilia. In PID, immunoglobulin treatment instead is obviously replacing a missing feature. However, other immune alterations are responsible for the large number of PID-associated diseases including inflammatory manifestations and tumors, common causes of morbidity and mortality. The immunomodulatory effects of immunoglobulin administered at replacement dosages on multiple cells and immune system functions are still largely to be checked in in vitro studies and in vivo. 2) the changes in the immunoglobulin production and schedules of administration. These should have been assessed in studies of drug surveillance, necessary in order to evaluate on large numbers of what it is initially reported on patients enrolled in the pivotal clinical trials, usually in the absence of most of the main disease-associated clinical conditions affecting pharmacokinetics, efficacy and tolerability. Severe side effects are now more frequently reported. This requires surveillance studies in order to verify the tolerability. Nowadays, personalized health research presents methodologic challenges, since emphasis is placed on the individual response rather than on the population. Even within a universally accepted indication, such as in PID, the identification of prognostic markers should guide the therapeutic intervention. 3) the risk of a decrease in the surveillance and monitoring of PID-associated clinical conditions. In fact, self- administration of immunoglobulins administered subcutaneously increased the independence of a number of patients. On the other hand, it led to the reduction in the number of contacts between specialized centers and patients who often require a close monitoring of disease-associated conditions. A wide debate between experts is necessary to afford the new challenge on immunoglobulin usage.


Periodical
Progress in Preventive Medicine
ISSN: 2473294X

Loading...
Export citation

Choose an application

Bookmark

Abstract


Dissertation
Conditions de mise en oeuvre du plan cafétéria dans le contexte belge
Authors: --- --- ---
Year: 2018 Publisher: Liège Université de Liège (ULiège)

Loading...
Export citation

Choose an application

Bookmark

Abstract

Belgium is one of the countries with the highest cost of labour due to high taxes and social charges. Nowadays organisations are looking for alternatives to reduce costs. However, in the other side employees are looking for more flexible benefits personalised to their needs and better suited to the diversity of their lifestyles. Actually, they are looking for benefits that could be more advantageous than the ones available at the workplace. Based on the current circumstances, the cafeteria plan is considered as one of the recommended solutions. It is in fact an employee benefits plan that allows employees, staff members to choose compensations package from a group of benefits already established by the employers. What are the effects of a cafeteria plan on an organisation? Is this cafeteria plan easy to implement? Is the plan legal in Belgium? How to create the needed budget? What type of benefits employees could select? Based on these considerations and thanks to our empirical study, we got to some conclusions regarding the possibility of implementing the cafeteria plan in the context of Belgium.


Book
Personalised cancer medicine future crafting in the genomic era
Authors: ---
ISBN: 1526141019 1526141027 Year: 2021 Publisher: Manchester, UK : Manchester University Press,

Loading...
Export citation

Choose an application

Bookmark

Abstract

This electronic version has been made available under a Creative Commons (BY-NC-ND) open access license. What does it mean to personalise cancer medicine? Drawing on an ethnographic study with cancer patients, carers and practitioners in the UK, this book traces their efforts to access and interpret novel genomic tests, information and treatments as they craft personal and collective futures. Exploring multiple experiences of new diagnostic tests, research programmes and trials, advocacy and experimental therapies, the authors chart the different kinds of care and work involved in efforts to personalise cancer medicine, as well as the ways in which benefits and opportunities are unevenly realised and distributed.Comparing these experiences with policy and professional accounts of the 'big' future of personalised healthcare, the authors show how hope and care are multi-faceted, contingent and, at times, frustrated in the everyday complexities of living and working with cancer.This book is available as an open access ebook under a CC-BY-NC-ND licence.


Book
Personalized Nutrition
Authors: --- ---
ISBN: 3039214462 3039214454 Year: 2019 Publisher: MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

“Personalised Nutrition” represents any initiative that attempts to provide tailor-made healthy eating advice based on the nutritional needs of each individual, as these are dictated by the individual’s behaviour, phenotype and/or genotype, and their interactions. This Special Issue of Nutrients is dedicated to the development, implementation and assessment of the effectiveness of evidence-based “Personalised Nutrition” strategies. In this regard, a selection of reviews and original research manuscripts will bring together the latest evidence on how lifestyle habits, physiology, nutraceuticals, gut microbiome and genetics can be integrated into nutritional solutions, specific to the needs of each individual, for maintaining health and preventing diseases.


Periodical
Food Production, Processing and Nutrition
ISSN: 26618974


Book
Pharmacogenetics to Avoid Adverse Drug Reactions
Author:
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.


Book
Pharmacogenetics to Avoid Adverse Drug Reactions
Author:
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.

Keywords

Medicine --- 5-fluorouracil --- capecitabine --- fluoropyrimidine --- thymidylate synthase --- thymidylate synthase enhancer region --- upstream stimulatory factor 1 --- adverse drug reactions --- pharmacogenomics --- epistasis --- random forest --- statin --- cardiovascular disease --- colorectal cancer --- personalised medicine --- toxicity --- (es)citalopram --- drug-gene-interaction --- drug-drug-interaction --- drug-drug-gene-interaction --- the PharmLines initiative --- antipsychotic agents --- pharmacogenetics --- cytochrome P-450 enzyme system --- psychotic disorders --- precision medicine --- direct oral anticoagulants --- clinical implementation --- atorvastatin --- SLCO1B1 --- HLA --- cutaneous adverse drug reaction --- SCAR --- genetic polymorphism --- antiepileptics --- CYP450 enzymes --- platelet reactivity --- single-nucleotide variants --- acute coronary syndrome --- clopidogrel --- genotype --- allele --- polymorphism --- HLA B --- CYP2C9*3 --- cutaneous adverse drug reactions (CADRs) --- anti-epileptic drugs (AEDS) --- phenytoin (PHT) --- genetic risk factors --- South India --- India --- cardiology --- adverse events --- guidelines --- 5-fluorouracil --- capecitabine --- fluoropyrimidine --- thymidylate synthase --- thymidylate synthase enhancer region --- upstream stimulatory factor 1 --- adverse drug reactions --- pharmacogenomics --- epistasis --- random forest --- statin --- cardiovascular disease --- colorectal cancer --- personalised medicine --- toxicity --- (es)citalopram --- drug-gene-interaction --- drug-drug-interaction --- drug-drug-gene-interaction --- the PharmLines initiative --- antipsychotic agents --- pharmacogenetics --- cytochrome P-450 enzyme system --- psychotic disorders --- precision medicine --- direct oral anticoagulants --- clinical implementation --- atorvastatin --- SLCO1B1 --- HLA --- cutaneous adverse drug reaction --- SCAR --- genetic polymorphism --- antiepileptics --- CYP450 enzymes --- platelet reactivity --- single-nucleotide variants --- acute coronary syndrome --- clopidogrel --- genotype --- allele --- polymorphism --- HLA B --- CYP2C9*3 --- cutaneous adverse drug reactions (CADRs) --- anti-epileptic drugs (AEDS) --- phenytoin (PHT) --- genetic risk factors --- South India --- India --- cardiology --- adverse events --- guidelines

Listing 1 - 10 of 26 << page
of 3
>>
Sort by